SCHEMBL25890238

SCHEMBL25890238

CN1C(=O)C(C)(O)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.55
MAPT P10636 5/20 0.53
LMNA P02545 4/20 0.53
KDM4E B2RXH2 2/20 0.53
HCRTR1 O43613 1/20 0.53
HTT P42858 5/20 0.49
TSHR P16473 2/20 0.49
ALDH1A1 P00352 4/20 0.49
PKM P14618 1/20 0.49
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CBX7 O95931 2/20 0.46
CDY1; CDY1B Q9Y6F8 2/20 0.46
MAPK1 P28482 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RECQL P46063 2/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1260714 0.80 MAPT (0.56) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL31238640 0.80 MAPT (0.56) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL27855190 0.79 ALDH1A1 (0.41) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL6744458 0.78 MAPT (0.54) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL29083889 0.78 MAPT (0.58) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL31294858 0.77 MAPT (0.53) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL25180711 0.77 ALDH1A1 (0.49) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL31389172 0.77 RAD52 (0.51) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL14101179 0.77 RAD52 (0.51) RAD52MAPTLMNAKDM4EHCRTR1
SCHEMBL31389174 0.77 RAB9A (0.58) RAD52MAPTLMNAKDM4EHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023237504-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-14 WO disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 RAD52 240/4885MAPT 4169/4885LMNA 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.